Regeneron CEO puts conditions on lowering his $14,000-per-year cholesterol drug
March 12, 2018 at 12:38 PM EDT
Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers make it easier to claim a reimbursement.
